Podcasts about MBC

In today's MadTech Daily, we discuss Meta's suspension of political ads in the EU and UK advertising rising 8% in the first quarter. We also cover strategic acquisitions in media with Netflix bundling with MBC, and Skydance sealing its deal with Paramount.

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics: Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00) Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49) Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44) Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29) Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19) CME information and select publications

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancerInteractive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancerOutcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs Program faculty:Laura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Shipra Gandhi, MD, MSAssociate ProfessorDirector, Breast Translational ResearchGlenn Family Breast CenterWinship Cancer Institute of Emory UniversityAtlanta, GeorgiaResources:To access the interactive patient cases associated with this podcast discussion, please visit the program page, to access a recording from a live webinar, and an interactive decision support tool on this topic.

1-2부 [뉴스 신세계] 1. 尹 집무실에 ‘비밀 사우나실'…김용현, 공사비 '현금 3천' 제안 2. “수거 대상 실미도서 사살” 노상원 메모…특검, 내란목적살인 예비죄 검토 3. 건진법사, 통일교 키맨에 "尹, MBC 없애려 해… 공포정치 피바람도 좋아" - 헬마우스 임경빈 작가 (출연)

1부 [JB TIMES] 尹 경호처, 용산 집무실 사우나 제작…'현금 거래' 제안 김건희 ‘日 왕실 납품' 진주 목걸이 착용…출처는? 건진, 윤영호에 ‘YTN 인수' 청탁 정황…”MBC 없애려 해” 尹, 내란재판 출석 못하지만 변호사 접견은 가능? 내란 특검, 한덕수 자택 압수수색…주목할 점은 당직자 폭행한 송언석 “강선우 의원직 사퇴해야” 대통령실 “전 정부 겨냥 과도한 정책감사 폐지” - 더 막내작가 [뉴스 채굴꾼] 김건희, 특검 조사 전 ‘아플 결심'하게 된다면? - 김연욱 작가

Neste episódio da série 'Cenários', Sonia Racy recebe Jorge Gerdau, presidente do Conselho Superior do MBC – Movimento Brasil Competitivo. O líder empresarial e reconhecido estrategista fala sobre a dificuldade desafiadora que é planejar hoje o futuro.See omnystudio.com/listener for privacy information.

Neste episódio da série 'Cenários', Sonia Racy recebe Jorge Gerdau, presidente do Conselho Superior do MBC – Movimento Brasil Competitivo. O líder empresarial e reconhecido estrategista fala sobre a dificuldade desafiadora que é planejar hoje o futuro.See omnystudio.com/listener for privacy information.

실종자 구조 수색 난항 + 이재명 "최선 다하라"폭우·폭염, 농축산물 물가 비상 질병철 "감염병 주의"드작사 영장 기각 김건희특검, 윤석열 29일·김건희 8월 6일 소환800-7070 주인은 윤석열 강선우 임명 기조에 반발 확산...장관에게까지 갑질 강준욱 국민통합 비서관 사퇴론 확산사제총기 살해 아버지 구속영장구윤철 "최대한 빨리 방미, 관세 협의"美재무 "신속보다 질 높은 합의 중요"조현 "MBC 제소는 잘못" 사과정성호 "수사권·기소권 분리 문제 매듭"See omnystudio.com/listener for privacy information.

In this episode, CancerNetwork® spoke with breast oncologists Heather McArthur, MD; Erika Hamilton, MD; Hope Rugo, MD; and Paolo Tarantino, MD, PhD, about advances in breast cancer. These developments included recent drug approvals and ongoing research for therapeutic approaches, particularly in the areas of antibody-drug conjugates (ADCs) and CDK4/6 inhibitors, based on presentations they gave at the 25th Annual International Congress on the Future of Breast Cancer (IBC) East in New York City. Initially, McArthur, Komen Distinguished Chair in Clinical Breast Cancer Research at the Harold C. Simmons Comprehensive Cancer Center, discussed immunotherapy use in high-risk triple-negative and HER2-positive disease, the evolving role of adjuvant CDK4/6 inhibition in HER2-negative breast cancer, and potentially transformative advancements in early breast cancer treatment.  She highlighted the FDA approval for pembrolizumab (Keytruda) in early-stage triple-negative breast cancer, promising clinical trials in estrogen receptor (ER)–positive high-risk early-stage breast cancer, and data from an investigator-initiated trial to treat HER2-positive disease. Additionally, she highlighted an 8.5% improvement in pathological complete response with pembrolizumab added to immunotherapy in the phase 3 KEYNOTE-756 trial (NCT03725059), adding that a further event-free survival benefit may complicate the landscape for CDK4/6 inhibition based on lung and liver toxicities associated with the coadministration of these inhibitors with immunotherapy.1 McArthur expressed further excitement for ADC-based combinations for triple-negative disease, as well as in the high-risk residual disease setting. In addition, she highlighted potential advancements in de-escalation strategies and further considerations for ADCs in the HER2-positive and hormone receptor (HR)–positive spaces. Then, Hamilton, director of Breast Cancer and Gynecologic Cancer Research at the Sarah Cannon Research Institute, highlighted emerging therapies for early breast cancer, as well as her use of datopotamab deruxtecan-dlnk (dato-DXd; Datroway) and fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) given their recent approvals in various breast cancer subtypes. She also touched upon challenges with respect to the implementation of new therapies for early breast cancer into clinical practice. She initially highlighted new data from the phase 3 VERITAC-2 trial (NCT05654623) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.2 Specifically, findings showed that vepdegestrant, an oral proteolysis-targeting chimera (PROTAC), exhibited an efficacy advantage over fulvestrant (Faslodex) in patients with ESR1-mutant ER-positive, HER2-negative advanced or metastatic disease. Moreover, she highlighted data from the phase 3 DESTINY-Breast09 (NCT04784715) of T-DXd in various combinations for patients with HER2-positive metastatic breast cancer.3 Hamilton further highlighted her implementation of T-DXd into clinical practice, citing her use of the agent in patients with metastatic disease, including those with HER2-low and HER2-ultralow breast cancer. She further differentiated dato-DXd from T-DXd, suggesting that they were different classes of drugs due to their different targets: TROP2 vs HER2. She concluded by highlighting an unmet need regarding sustained benefit from endocrine therapy in HR-positive disease, as well as for ADC sequencing and mechanisms of resistance. Afterward, Rugo, division chief of Breast Medical Oncology, Women's Cancer Program Director, and professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discussed efficacy and safety considerations for CDK4/6 inhibitors in early breast cancer treatment. Specifically, she highlighted their high tolerability despite adverse effects and costs associated with their use. Rugo further touched upon a reduction of recurrence rates associated with CDK4/6 inhibition, although longer-term follow-up data were warranted to optimize the duration of therapy and elucidate survival outcomes. Finally, Tarantino, a research fellow at the Dana-Farber Institute, concluded by discussing sequencing strategies for ADCs, as well as which breast cancer settings or patient populations will experience the greatest impact with this treatment modality. Tarantino discussed his use of the “sandwich strategy,” where he switches the mechanism of action of treatment after using a TOPO1 ADC. Furthermore, Tarantino highlighted data from the DESTINY-Breast09 and phase 3 ASCENT-04 (NCT06100874) trials, which displayed the enhanced efficacy of 2 ADC combination therapies.4 He concluded by discussing future considerations for combining multiple ADCs. References 1. Cardoso F, O'Shaughnessy J, Liu Z, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):442-448. doi:10.1038/s41591-024-03415-7 2. Hamilton E, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: results of the global, randomized, phase 3 VERITAC-2 study. J Clin Oncol. 2025;43(suppl 17):LBA1000. doi:10.1200/JCO.2025.43.17_suppl.LBA1000 3. Tolaney S, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): interim results from DESTINY-Breast09. J Clin Oncol. 2025;43(suppl 17):LBA1008. 4. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. J Clin Oncol. 2025;43(suppl 17):LBA109. doi:10.1200/JCO.2025.43.17_suppl.LBA109

Jon Pole, President of My Broadcasting Corporation, believes some of radio's best days are still ahead.The second-generation broadcaster joins Broadcast Dialogue - The Podcast to talk about MBC's continued growth, now positioning the company as one of the biggest independent radio operators in Ontario.We also get into the Canadian content debate and regulatory burden on stations, and why Pole says his radio group bucking downward sales trends.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

3부 [이슈 인터뷰 2] 윤희숙 '다구리' 폭로에 전한길 입당까지, 국민의힘 '내홍' - 호준석 국민의힘 대변인·혁신위원 [이슈 인터뷰 3] 외교부, MBC '바이든-날리면' 소송 취하 시사...기자의 소회는? - 임현주 MBC 기자

[연장인터뷰] 외교부, MBC '바이든-날리면' 소송 취하 시사...기자의 소회는? - 임현주 MBC 기자 [정치어때] 이진숙·강선우 임명? 지명철회? & 인사청문회 주목할 장면은 - 홍익표 전 더불어민주당 의원, 오신환 전 국민의힘 의원

El Ayuntamiento de Rincón de la Victoria avanza en las obras de renovación y mejora de la calle Antonio de Hilaria, alcanzando ya el 90% de ejecución. Los trabajos, con una inversión de 150.220 euros financiados por el Plan de Asistencia Económica Municipal (PAEM 2024 – 4ª fase) de la Diputación Provincial de Málaga, consisten en la renovación del asfaltado en un tramo de 4.646 metros cuadrados comprendido entre el IES Bezmiliana y la guardería municipal, conectando también con el CEIP Profesor Tierno Galván y la Biblioteca Pública Municipal. El concejal de Obras y Servicios, Sergio Díaz (PP), ha señalado que “la actuación, que marcha a buen ritmo, supondrá dotar de mayor seguridad a una zona urbana con una alta densidad de tráfico tanto rodado como peatonal, especialmente en horarios escolares”. Por su parte, el alcalde de Rincón de la Victoria, Francisco Salado (PP), ha destacado “la importancia de estas obras para la mejora de las infraestructuras viarias en un entorno muy transitado por estudiantes, familias y vecinos de la zona, mejorando la circulación y aumentando la seguridad vial”. Entre las actuaciones ya ejecutadas se encuentran el fresado del pavimento y la reposición de la capa de rodadura de mezcla bituminosa en caliente (MBC). En los próximos días se completará la señalización horizontal, además de la instalación de tres reductores de velocidad tipo lomo de asno y un paso peatonal sobreelevado. También se están sustituyendo tapas de arquetas, pozos y sumideros para garantizar un correcto funcionamiento de las infraestructuras municipales. Además, en el marco de este proyecto, se está procediendo a la instalación de diversos elementos reductores de velocidad en otras zonas del municipio, como el Paseo de Filipinas, calle Sorolla, Camino Viejo de Vélez (en varios tramos), Avenida de Jábega, Camino del Cementerio, calle Mediodía y calle La Loma, con el objetivo de reforzar la seguridad de los peatones. La ejecución de las obras está siendo llevada a cabo por la empresa adjudicataria Probisa.

The power of opposition is intense. History has proved again and again how empires have fallen when facing internal weakness and external pressure. From the Persians seeing Alexander the Great sweep across the known world, to the Inca and Aztec’s falling to Spanish conquistadors, and the Western Roman Empire collapsing under the attacks of small Germanic tribes, it is amazing how opposition exploits weaknesses. Nehemiah and the people were making great progress on the walls, but Sanballat, Tobiah the Ammonite, the Arabs, and men of Ashdod were not ok with Jerusalem coming back to power. They began use weapons of mass disruption by taunting the workers and ridiculing their efforts. Sadly, this would likely be enough to deter many today from the Lord’s work. The people held strong through prayer, but then faced the threat of physical attack. This was no longer a group of bullies, but a real life threatening situation with enemies on all sides growing impatient, and putting their destruction. This brought on the natural discouragement of doing hard work under pressure, and the constant fear of attack and failure. For each of us today these same things plague our lives. From ridicule and threat, to discouragement and fear we all constantly see opposition from outside and within. There is a reality of an enemy who hates us. There is the sinful flesh that distracts us. Both of these desire to destroy us. How do we battle them and keep walking in obedience to God’s call? By doing what Ephesians 6 tells us, and armoring up! Join us for one of our worship services this weekend and MBC as we continue in the book of Nehemiah! - Pastor Ben Key Verse - Nehemiah 4:9 - "But we prayed to our God and posted a guard day and night to meet this threat." For Scripture, notes, upcoming events, & more: http://bible.com/events/49450999

30th 경제콘서트 인공지능의 시대, 대한민국 반도체 산업의 생존전략 w. 김정호 카이스트 전기 및 전자공학과 교수 일시: 2025년 6월 28일 (토) 오후 2시 장소: 상암 MBC 골든마우스홀 출연: 김정호 카이스트 전기 및 전자공학과 교수, 이진우 기자

Pastor Mike Weber visits MBC to share a message on Psalm 51.

Send us a textJoin us for a candid & heartfelt discussion with certified death doula and fellow MBCer Deltra James as she shares how death doulas support us in facing mortality with less fear and more intention. We also chat about her six week virtual course, “The Good Grim: Exploring end of life, facing fears, and living fiercely”, offered free through Project Life for those living with MBC. We invite you to listen to this life-filled conversation. Please visit our website, Our MBC Life, to check out the information provided in the episode notes. 

"In my mind, I'm not going anywhere anytime soon." It's been a whirlwind week. THANK YOU for all of the love, support, and kindness after last week's "we're due for a catch-up" episode. It's been an overwhelming time for me — but what about for my support squad? I get so many questions from people asking how best to show up for someone going through a hard time, and my team and I have learned a lot about what this can all look like. So for this one, Cousin Jackie returns, and we're talking about what the past few weeks have been like for each of us: the patient and the support person. SPONSORS:  Oofos: The best in recovery footwear! Check out Oofos's 2025 Project Pink collection, where 10% of every purchase is donated to cancer research.  Vuori: Click here for 20% off your first Vuori purchase. Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!

Today we hear from several teachers across the Treasure State who have been able utilize beef grant gift cards to further student education on beef cuts and cooking techniques. The partnership with MBC and the Montana Family and Consumer Sciences is in it's second year with increasing interest from teachers in Montana. See omnystudio.com/listener for privacy information.

3-4부 [이슈 하이킥2] 국민의힘 패배 이후의 해법은? - 정성국 국민의힘 의원(출연) [이슈 하이킥3] 6·3 대선 총정리 민심은 왜 이재명을 택했나 - 김봉신 메타보이스 부대표, 장슬기 MBC 기자(출연)

Lee Jae-myung of South Korea's majority liberal Democratic Party was elected president, the ongoing vote count by the National Election Commission showed on Wednesday.韩国中央选举管理委员会周三进行的计票显示，韩国执政党共同民主党的李在明当选总统。With 94.4 percent of the votes counted after midnight, Lee won 48.8 percent and his major rival Kim Moon-soo of the conservative People Power Party took 42.0 percent, the National Election Commission data showed.据中央选举管理委员会的数据显示，午夜后已统计94.4%的选票，李在明获得48.8%的选票，其主要竞争对手、保守派国民力量党的金文洙获得42.0%的选票。Even if all the remaining uncounted votes go to Kim, Lee will win the presidential by-election, confirming his victory.即使所有剩余未计票都投给金文洙，李在明也将赢得总统补选，确立其胜选地位。Local broadcaster JTBC and three terrestrial broadcasters including KBS, MBC and SBS forecast earlier that Lee was certain to be elected the country's 21st president.韩国地方电视台JTBC以及KBS、MBC和SBS等三家地面电视台此前预测，李在明必将当选韩国第21任总统。Preliminary voter turnout reached 79.4 percent, marking the highest in 28 years since the voting rate recorded 80.7 percent in 1997.初步数据显示，选民投票率达到79.4%，为28年来最高纪录，上一次投票率达到80.7%是在1997年。Out of about 44.39 million eligible voters, some 35.24 million cast their ballots at 14,295 polling stations across the country.在约4439万合格选民中，约3524万人在全国14295个投票站投票。The voter turnout, which included those who participated in early voting last Thursday and Friday, was up from 77.1 percent tallied in the previous presidential election in 2022.包括上周四和周五提前投票的选民在内，本次投票率高于2022年上届总统选举的77.1%。liberal/ˈlɪbərəl/adj.自由派的；主张变革的turnout/ˈtɜːrnaʊt/n.出席人数；投票率eligible/ˈelɪdʒəbl/adj.有资格的；合格的forecast/ˈfɔːrkæst/v./n.预测，预报

In this raw, refreshing, and beautifully honest episode, Wren, the founder of the Living Our Breast Lives Podcast is joined by the vibrant Bethany Adair—a woman who's not just living with Metastatic Breast Cancer (MBC), but living the f*ck out of life despite it. From the moment she opens up, Bethany invites us beyond the diagnosis and into her world: her passions, her community, her writing, and her unshakable authenticity.We explore the realities of MBC—from diagnosis and treatment to mental health, anxiety, and the emotional exhaustion that comes with being seen as “the strong one.” Bethany shares how she balances joy and grief, hope and hardship, strength and softness—all while building a life filled with meaning and purpose.She also talks about breaking the mold of toxic positivity in the cancer space, and why vulnerability might just be the bravest act of all. As an author, she opens up about how Metastatic Breast Cancer has shaped her voice and the messages she wants to share with the world.Whether you're living with MBC, love someone who is, or just want to hear a powerful story about resilience, identity, and living out loud—this episode is for you. It's real, it's raw, it's relatable, and most importantly—it's a reminder that life is still worth living, even in the messiest, most uncertain moments.Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrBethany Adair's Information:Email: Bethany@mygurucancer.comWebsite: www.mygurucancer.comBook: My Guru Cancer: You Don't Have to Fight to Find True Freedom from the C Word (found on Amazon + most online retailers)Instagram: @mygurucancerFacebook: @mygurucancer TikTok: @mygurucancerNewsletter: http://eepurl.com/bySU1X

Roy Patterson, longtime friend of MBC, blesses us with a message on areas that we need to submit and allow the Lord to continually change and renew our minds. (Mark 6:34-44)

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:Key Comorbidities in Patients with HR+/HER2- MBCImpact of PolypharmacyRole of APPs in Comprehensive CareRole of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBCUtility of RWE dataCommunicating Treatment Options With Patients and CaregiversUnderstanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of LifeLink to full program:https://bit.ly/4jCQe38

Amy Austin returns to The Burn for a second visit. Amy was diagnosed with Stage IV de novo breast cancer at 34 after initially being misdiagnosed with a complex benign cyst. She is the third in a direct family line to be diagnosed with breast cancer without a known genetic link. In this episode Amy reads her poem “In Praise of Quiet Advocacy” from the 2024 “MBC: Advocacy” issue of Wildfire Journal. Her poem is about the role of “quiet” advocacy in supporting individuals living with metastatic breast cancer (MBC). April and Amy will discuss what quiet advocacy means, the importance of being seen and seeing other young breast cancer patients, and the impact of friendships when sharing an MBC diagnosis. Amy will also share how her poem came to be with the support of another MBC friend, and the writing prompts that are all around us.More about Amy: https://www.instagram.com/amy_r_austin/Purchase the “MBC: Advocacy” issue of Wildfire Magazine: https://www.wildfirecommunity.org/shop/p/digital-mbc24Buy the Wildfire book Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860Get the free Wildfire “Hot Flashes” email newsletter: https://www.wildfirecommunity.org/newsletter?rq=newsletterListen to another episode featuring Amy: https://player.captivate.fm/episode/997971a0-b861-4698-aca8-7f4b82c90056Learn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shop*Free* Get Wildfire and The Burn freebies here: https://www.wildfirecommunity.org/freeMore about Wildfire Magazine: https://www.wildfirecommunity.orghttps://www.instagram.com/wildfire_bc_magazine/https://www.facebook.com/wildfirecommunityInformation on submitting your story for consideration to be published in Wildfire Magazine: https://www.wildfirecommunity.org/submissions

1-2부 [뉴스 신세계] 1. 결과공표기간 전 마지막 여론조사 2. 대선 후보 3차 TV토론...어떤 말 오갔나? 2-1 이준석 '부적절 발언' 논란 일파만파..."심심한 사과" 3. 사전투표 D-1…김문수-이준석 단일화 사실상 불발 - 헬마우스 임경빈 작가 (출연) [이슈 하이킥1] 대선 D-6... 민심 흐름은? - 김봉신 메타보이스 부대표 - 장슬기 MBC 기자 (출연)

3-4부 [이슈 하이킥2] 여론조사로 본 대선 정세… 표심은 어디로? - 김봉신 메타보이스 부대표, 장슬기 MBC 기자(출연) [이슈 하이킥3] “광장의 목소리 대변하겠다…”권영국, 진보의 길을 묻다 - 권영국 민주노동당 후보(전화)

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Send us a textIn this episode of Our MBC Life, we sit down with Dr. Kelly Shanahan, the president of METAvivor, a U.S. nonprofit solely dedicated to funding research for metastatic breast cancer (MBC) while also supporting patients through advocacy and community. Our guest shares METAvivor's mission, their biggest milestones, and how their work is driving critical research that aims to extend lives and improve quality of life for those living with MBC.We dive into how METAvivor prioritizes research funding, the importance of patient involvement in advocacy initiatives, and the Stage IV Stampede—a powerful advocacy event raising awareness and amplifying the voices of the MBC community.Tune in to hear how METAvivor is shaping the future of MBC advocacy and how you can get involved to make an impact

In this episode Annie talks about breaking up and dating while living with MBC. Don't miss this one!@theanniebond Each week, Heather shares profound insights gained from her remarkable 25-year journey as a metastatic breast cancer survivor. Join us as we delve into essential topics like cancer survivorship, where Heather and Larry impart valuable mental health advice and coping strategies for cancer patients. From navigating hospitals to post-treatment tips, Heather's candid and compassionate narrative serves as a beacon of strength. Tune in for an intimate exploration of coping mechanisms, including Heather's personal journey insights, as she imparts wisdom on resilience, hope, and living life to the fullest despite the challenges of metastatic breast cancer. If you or a loved one is seeking authentic guidance, this podcast provides a wealth of information, ensuring that no one faces cancer alone. Check out our newly designed 5 to Thrive Guides at www.heatherjose.com/products. Follow Heather's Socials: Instagram: HeatherbjoseLinkedIn: ⁠ / heatherjose ⁠ Youtube: @ImStillHereCancer Little Pink Houses of Hope Provides Free Vacations for People with Breast Cancer- ⁠https://www.littlepink.org/⁠ ⁠#MetastaticBreastCancer⁠ ⁠#Deconstruct⁠ ⁠#Deconstruction⁠ ⁠#CancerSurvivor⁠ ⁠#ThrivingWithCancer⁠ ⁠#MentalHealthMatters⁠ ⁠#NutritionForWellness⁠ ⁠#MedicalAdvancements⁠ ⁠#MindfulnessJourney⁠ ⁠#ResiliencePodcast⁠ ⁠#PatientAdvocacy⁠ ⁠#TreatmentInsights⁠ ⁠#SurvivorStories⁠ ⁠#PodcastHope⁠ ⁠#CommunitySupport⁠ ⁠#EmpowermentPodcast⁠ ⁠#LivingBeyondDiagnosis⁠ ⁠#PositiveMindset⁠ ⁠#WellnessWednesday⁠ ⁠#CancerAwareness

3-4부 [이슈하이킥2] ‘원팀'으로 갈 수 있을까… 국힘 내부 흐름 진단 - 정성국 국민의힘 의원(출연) [이슈하이킥3] 영남에서 뒤엉킨 3자 대결…이재명 vs 김문수 vs 이준석 -김봉신 메타보이스 부대표 장슬기 MBC 기자(출연)

This featured podcast includes a data review and candid conversation with 4 experts on challenges in the current treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) due to endocrine resistance. This session occurred during a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025.  ESR1 mutations are a critical mechanism of resistance, spurring the development of next-generation endocrine agents targeting these mutations. These agents including oral selective estrogen receptor degraders (SERDs) and agents with novel mechanisms, including proteolysis-targeting chimeras (PROTACs), which may offer potential improvements over current treatments. This program will review mechanisms of resistance to current endocrine regimens, strategies to overcome this resistance including comparative mechanisms of novel endocrine agents, emerging data from ongoing clinical trials, and expert perspectives on where these new agents may fit into current algorithms.

[이슈하이킥2] D-27… 여론조사로 분석한 대선 판세는? - 김봉신 메타보이스 부대표, 장슬기 MBC 기자 [이슈하이킥3] 김문수-한덕수 11일 전 단일화 가능할까? - 윤희석 전 국민의힘 대변인

Egyptian actor, producer, TV host and doctor Mohamed Karim? Mohamad can be seen in the Lionsgate film Gunslingers releasing in theatres on April 11, 2025 alongside Nicolas Cage, Heather Graham and Stephen Dorff! This action-packed drama western is sure to keep you on the edge of your seat, following the story of reformed gunslinger (Dorff) and mad genius (Cage) who are guided by a spiritual leader towards vindication. While confronting their violent histories, their newfound peace is challenged by violence and revenge. Not stopping there, after wrapping a starring role in the American independent film Storm, Karim has signed on to star in the upcoming American project Desert Crossing and three British films: Tarot, Blooded, and One Love. Mohammad is best known for his lead role in popular TV series Bent Afandina, a story about the revolution in Egypt from 1952 until 1970 (the period between King Farouk until President Anwar Sadat). This TV series put him on the map all over Egypt and The Middle East, where he won the Best Actor Award in 2004. He can also be seen as Detective Reynolds in Bruce Willis' final film A Day to Die and as a lead role playing Jimmy the Dragon alongside Nicholas Cage and Benjamin Bratt in the 2019 action thriller A Score to Settle. In 2012, Mohamed had the opportunity and honor to host the well-known international singing competition show The Voice: Arabia season 1 and 2 in the Middle East on MBC channels.   Want to watch: YouTube Meisterkhan Pod. (Please Subscribe)

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics: Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00) Comparing safety profiles of CDK4/6 inhibitors (9:49) Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06) Real-world evidence with CDK4/6 inhibitors (27:31) CME information and select publications

3부 [이슈 인터뷰 2] '중국인 혐오' 현수막, 폭력 범죄의 전조? 규제 방안은? - 홍성수 숙명여대 법학부 교수 [이슈 인터뷰 3] 피고인석 앉은 尹 첫 공개... '내란 2차 공판' 취재 후기 - 송정훈 MBC 기자

There have been so many views of Jesus developed throughout the year, yet most of them fall far short or are completely false. That is why it is so important for us to know the words Jesus himself spoke to describe who He is! There is no need for a guessing game, arguments, or stretches of the imagination to know Him. He has made Himself known clearly. Jesus is the visible image of the invisible God (Col. 1:15). He is God in flesh, who has dwelt among us (John 1:1-14). He is the Lamb of God who has taken away the sin of the world (John 1:29). He is the One through whom all things were made (John 1:3). Each of these statements of who Jesus is could be seem as claims from others about Him… So what does He Himself claim to be? John 14:6 tells us that Jesus claims to be “The Way, The Truth, and The Life”. This is a HUGE claim from Him, and if it is correct it changes EVERYTHING. Spoiler alert… It IS correct! Come and join us for one of our Easter worship services at MBC where we will look into who Jesus himself says He is! -Pastor Ben Key Verse - John 14:6 (NIV) - "Jesus answered, "I am the way and the truth and the life. No one comes to the Father except through me." For Scripture, notes, upcoming events, & more: http://bible.com/events/49414344

Please visit answersincme.com/BCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for the management of hormone receptor–positive, HER2-negative metastatic disease. Upon completion of this activity, participants should be better able to: Identify the available TROP2-directed ADCs for management of HR+, HER2- metastatic breast cancer (mBC); Outline the efficacy and safety of available and emerging TROP2-directed ADCs for HR+, HER2- mBC; and Apply personalization factors to help identify the optimal therapy for each individual patient with HR+, HER2- mBC.

Featuring an interview with Dr Adrienne G Waks, including the following topics: The Phase III AFT-38 PATINA trial of palbociclib combined with anti-HER2 therapy for hormone receptor (HR)-positive/HER2-positive metastatic breast cancer (mBC) (0:00) Role of immunotherapy in the treatment of breast cancer (8:30) Defining ER-low breast cancer and identifying treatment approaches for this histologic subtype (15:55) Genomic testing approaches for patients with localized breast cancer and identification of candidates for treatment with adjuvant olaparib (19:37) Current role of anthracyclines in the treatment of localized breast cancer (31:17) Available and novel antibody-drug conjugates for the treatment of breast cancer (41:21) Palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for HR-positive, HER2-negative mBC (51:53) CME information and select publications

Featuring a slide presentation and related discussion from Dr Adrienne G Waks, including the following topics: Updated analyses from key studies of the 21-gene Recurrence Score® for localized ER-positive breast cancer (29:30) Four-year landmark analysis of the NATALEE trial of adjuvant ribociclib with nonsteroidal aromatase inhibitor for localized breast cancer (9:49) The PADMA trial of palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (mBC) (11:25) Imlunestrant with or without abemaciclib for metastatic ER-positive mBC (13:18) TROP2-directed antibody-drug conjugates (ADCs) datopotamab deruxtecan and sacituzumab tirumotecan for HR-positive/HER2-negative mBC (17:50) Recent analyses from the DESTINY-Breast06 trial of trastuzumab deruxtecan (T-DXd) after endocrine therapy for HR-positive, HER2-low or HER2-ultralow mBC (21:09) The ICARUS-BREAST01 Phase II trial of the HER3-targeted ADC patritumab deruxtecan for HR-positive/HER2-negative mBC (26:02) Updates from neoadjuvant/adjuvant trials of pembrolizumab (KEYNOTE-522) and atezolizumab (NSABP B-59/GBG 96-GeparDouze) for localized triple-negative breast cancer (TNBC) (27:36) Ten-year update of the OlympiA trial of adjuvant olaparib for patients with germline BRCA1/2-mutated HER2-negative localized breast cancer (31:23) Exploratory analysis of patients who did or did not receive prior PD-1/PD-L1 inhibition in the Phase III OptiTROP-Breast01 study of sacituzumab tirumotecan versus chemotherapy for previously treated advanced TNBC (32:56) CNS efficacy of T-DXd (DESTINY-Breast12 trial) and outcomes with palbociclib combined with anti-HER2 therapy (AFT-38 PATINA trial) for HER2-positive mBC (34:04) CME information and select publications

Send us a textSenior Producer & Host Martha Carlson interviews Josh Newby, the founder of Theresa's Research Foundation. Josh has been a leader in the world of metastatic breast cancer advocacy for over a decade, focusing energy on bringing MBC research scientists and patient advocates together in an effort to improve our lives. To paraphrase Josh, researchers need patients and patients need researchers—a synergy he recognized early and brought to the fore of advocacy. This year, Josh and Theresa's Research Foundation is doubling down on a cure for MBC. In this episode, he talks about the work the Foundation is doing and what “cure” means to him. He also talks about the effects of current federal policy on research and what it may mean for the young MBC investigators he champions. To check out the episode notes, please visit ourmbclife.org. 

Join Wren Morrobel, founder of the Living Our Breast Lives podcast, and Darylene Finkelstein, founder of the Charlotte METsters support group, as they dive into what it takes to start your own in-person support group! In this episode, Dar shares all the tips, tricks, do's, and don'ts to help you create a thriving support network wherever you are in the U.S. While some find comfort in online communities, others long for in-person connections and friendships. What if you could be the one to bring people together—just like Dar has for so many in the Charlotte METsters group?Dar Finkelstein—70 years old, on her eleventh line of treatment, and a dedicated patient advocate, wife, mom, and stage four metastatic breast cancer thriver—is on a mission to build community and support those living with MBC in the greater Charlotte area. But she's not stopping there—she's determined to teach others across the country how to do the same!Listen and start your very own in-person support group today! Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morr

Featuring an interview with Dr Sara A Hurvitz, including the following topics: Role of endocrine therapy in the management of HER2-positive breast cancer; implications of the Phase III PATINA study (0:00) Case: A woman in her mid 60s with node-negative, HR-positive, HER2-negative localized breast cancer and a Recurrence Score® of 28 (8:38) Available data guiding the selection of an adjuvant CDK4/6 inhibitor (12:49) Selection of a CDK4/6 inhibitor in the metastatic setting (23:16) Available therapies for patients with HR-positive metastatic breast cancer (mBC) and PIK3CA mutations; implications of the Phase III INAVO120 study (29:17) Case: A woman in her early 60s with HR-positive, HER2-negative mBC with short duration of benefit from a first-line CDK4/6 inhibitor and an aromatase inhibitor (AI) and coexisting PIK3CA and ESR1 mutations (37:11) Available data with approved and investigational oral SERDs (selective estrogen receptor degraders) (43:23) Case: A woman in her early 70s with HR-positive, HER2-negative mBC and an ESR1 mutation detected on disease progression after durable responses to first-line endocrine therapy and second-line CDK4/6 inhibitor with an AI (51:38) Selection of therapy for patients with HR-positive mBC and coexisting targetable genetic mutations (53:11) Case: A woman in her late 50s with HR-positive, HER2-negative mBC and an ESR1 mutation detected on disease progression after first-line CDK4/6 inhibitor with an AI (1:00:17) CME information and select publications

1부 [JB TIMES] ‘이재명 무죄'에 권성동·권영세, 재판부 공격? 이정섭 검사 공소장 공개…'뒤캐기'와 ‘삥뜯기'? 안창호 인권위원장 “한겨레·경향·MBC 보지 마라” 산불 현장서 기념사진 찍은 서석영 경북도의원 논란 - 더 막내작가

Danny Moses is joined by Ivy Zelman, Founder and Executive VP of Zelman Associates, to discuss her career and insights into the housing market. Ivy shares her journey from a financial analyst at Solomon Brothers in the 1990s to becoming a renowned figure in the housing sector. They delve into her famous predictions on the housing market downturn, the impacts of the 2008 financial crisis, and her strategies for maintaining accurate market forecasts. The conversation also explores current market challenges such as affordability, immigration, tariffs, and declining home sales, along with her perspectives on builders, mortgage rates, and industry consolidation. Ivy also shares details about her memoir 'Gimme Shelter' and her ongoing work at Zelman Associates. On The Tape on X: https://x.com/OnTheTapePod Danny Moses on X: https://x.com/dmoses34 Ivy Zelman's Stock Disclosures: AMWD, BLD, BLDR, CSL, FBHS, IBP, MBC, RMAX, SWK, BZH, CCS, HOV, KBH, LEN, MDC, MHO, MTH, PMH, TOL & TMHC Stock Ownership: Analyst: No Analyst's Family: No Analyst's Firm: No Investment Banking Client: No Other Conflicts: Yes – Zelman has received compensation for products or services other than investment banking services.   DFH Stock Ownership: Analyst: No Analyst's Family: No Analyst's Firm: No Investment Banking Client: Yes Other Conflicts: Yes – Zelman has received compensation for products or services other than investment banking services -- ABOUT THE SHOW For decades, Danny has seen it all on Wall Street and has built his reputation on integrity, curiosity and skepticism that he will bring with him each week. Having traded through the Great Financial Crisis and being featured in "The Big Short" is only part of the experiences Danny wants to share with the listener. This weekly podcast cuts through market noise, offering entertaining and informative discussions with expert guests giving their views of the financial world and the human side of it. Whether you're a seasoned investor or just getting started, On The Tape provides something for all listeners. Follow Danny on X: @dmoses34 The financial opinions expressed are for information purposes only. The opinions expressed by the hosts and participants are not an attempt to influence specific trading behavior, investments, or strategies. Past performance does not necessarily predict future outcomes. No specific results or profits are assured when relying on this content. Before making any investment or trade, evaluate its suitability for your circumstances and consider consulting your own financial or investment advisor. The financial products discussed in 'On The Tape' carry a high level of risk and may not be appropriate for many investors. If you have uncertainties, it's advisable to seek professional advice. Remember that trading involves a risk to your capital, so only invest money that you can afford to lose. Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service.

We are blessed once again to have our Metropolis Youth & Young Adult Director Panos with us this morning. His youth sermon (which begins at the 30 second mark) focuses on the Saint we remember on this 2nd Sunday of Great Lent, St. Gregory of Palamas and a practice that is done at MBC.What is it?LISTEN!

Bethany Adair was diagnosed at 34 with Stage II breast cancer, and is now living with Stage IV metastatic disease. She is a mindset coach, speaker, MBC thriver and author of My Guru Cancer. In this episode, Bethany reads her piece “A Letter to My Greatest Guru” from Wildfire Magazine's 2023 “MBC: Lesson Learned” issue. Her essay is about viewing a cancer experience as an opportunity to grow into an authentic version of yourself. April and Bethany will talk about how Bethany became a writer, reframing thoughts and the ongoing practice of living alongside cancer. More about Bethany: https://www.instagram.com/mygurucancer/?hl=enhttps://bethanywebb.com/mygurucancer/blog-my-guru-cancer/This episode was brought to you in collaboration with After Breast Cancer Diagnosis (ABCD):https://abcdbreastcancersupport.org/https://www.instagram.com/abcdafterbreastcancerdiagnosis/https://www.facebook.com/ABCDAfterBreastCancerDiagnosis/?ref=tshttps://www.youtube.com/channel/UCY4VHSTPyU1IYyT1fNesmAgPurchase the “MBC: Lessons Learned” issue of Wildfire Magazine: https://www.wildfirecommunity.org/shop/p/mbc23If you liked this episode, you might like “A Guest Room for MBC with Erin Weiss”: https://player.captivate.fm/episode/82d235ba-6267-410c-ab29-c0abbc9bde27/Buy the Wildfire book Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860Get the free Wildfire “Hot Flashes” email newsletter: https://www.wildfirecommunity.org/newsletter?rq=newsletterLearn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shop*Free* Get Wildfire and The Burn freebies here: https://www.wildfirecommunity.org/freeMore about Wildfire Magazine: https://www.wildfirecommunity.orghttps://www.instagram.com/wildfire_bc_magazine/https://www.facebook.com/wildfirecommunityInformation on submitting your story for consideration to be published in Wildfire Magazine: